Literature DB >> 22361286

Menus for managing patients with cutaneous T-cell lymphoma.

Brian Poligone1, Peter Heald.   

Abstract

In the management of patients with cutaneous T-cell lymphoma (CTCL), there are numerous distinct therapy options. Each of these therapies is discussed in terms of when to use it, what factors limit the success of the treatment, and what to expect. A menu is defined as a list of items from which to choose. The treatments for CTCL are presented in various menus where they are options for a particular goal in a particular setting of CTCL. The best recognized clinical scenarios of CTCL are those recognized by the staging system: limited patch plaque (T1), disseminated patch plaque (T2), erythroderma (T4), and tumor (T3). Each phase of the disease will have the menu of therapy options presented for a given goal of management. Copyright Â
© 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22361286      PMCID: PMC3684429          DOI: 10.1016/j.sder.2011.12.002

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  42 in total

1.  High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.

Authors:  Stephen K Richardson; Julie H Lin; Carmela C Vittorio; Ellen J Kim; Jessica S Yoon; Jacqueline Junkins-Hopkins; Alain H Rook
Journal:  Clin Lymphoma Myeloma       Date:  2006-11

2.  Long-term follow-up of photodynamic therapy for mycosis fungoides.

Authors:  Desiree Wiegleb Edström; Mari-Anne Hedblad
Journal:  Acta Derm Venereol       Date:  2008       Impact factor: 4.437

3.  Six patients with early-stage cutaneous T-cell lymphoma successfully treated with topical 5-fluorouracil.

Authors:  Ajith P Kannangara; Denise Levitan; Alan B Fleischer
Journal:  J Drugs Dermatol       Date:  2010-08       Impact factor: 2.114

4.  Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.

Authors:  Julie de Quatrebarbes; Eric Estève; Martine Bagot; Philippe Bernard; Marie Beylot-Barry; Michele Delaunay; Michel D'Incan; Pierre Souteyrand; Loïc Vaillant; Nadège Cordel; Philippe Courville; Pascal Joly
Journal:  Arch Dermatol       Date:  2005-09

5.  Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.

Authors:  Arturo Molina; Jasmine Zain; Daniel A Arber; Maria Angelopolou; Margaret O'Donnell; Joyce Murata-Collins; Stephen J Forman; Auayporn Nademanee
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

6.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Authors:  Madeleine Duvic; Rakshandra Talpur; Xiao Ni; Chunlei Zhang; Parul Hazarika; Cecilia Kelly; Judy H Chiao; John F Reilly; Justin L Ricker; Victoria M Richon; Stanley R Frankel
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

7.  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rafael F Duarte; Carmen Canals; Francesco Onida; Ian H Gabriel; Reyes Arranz; William Arcese; Augustin Ferrant; Guido Kobbe; Franco Narni; Giorgio Lambertenghi Deliliers; Eduardo Olavarría; Norbert Schmitz; Anna Sureda
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

8.  Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Elise A Olsen; Debra Breneman; Theresa R Pacheco; Sareeta Parker; Eric C Vonderheid; Rachel Abuav; Justin L Ricker; Syed Rizvi; Cong Chen; Kathleen Boileau; Alexandra Gunchenko; Cesar Sanz-Rodriguez; Larisa J Geskin
Journal:  Clin Lymphoma Myeloma       Date:  2009-12

9.  Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides.

Authors:  P Ponte; V Serrão; M Apetato
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-11-19       Impact factor: 6.166

10.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

Authors:  Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.